ClinicalTrials.gg
CompletedNCT02711852Updated Sep 11, 2023Results posted

A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)

A Phase 2 interventional study of Duvelisib in Hematologic Malignancy, sponsored by SecuraBio. Completed at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-11.

Sponsored by SecuraBio · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 823 studies in Hematologic Neoplasms with a site in United States — 182 open to participants now, 278 under way, 12 of them phase 3. Hematologic Neoplasms · United States.

Enrollment
484th of 660
19 · median 40
Started
2016
with 44 others
Phase 2
194 of 823
25 open now
Registered
351st of 823
by date

Among the 823 studies in Hematologic Neoplasms with a site in United States, this one is the 484th largest by enrollment of the 660 interventional ones that give a count, is one of 45 that started in 2016, is one of 194 in phase 2, and was the 351st registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 421 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

182 of the 823 studies in Hematologic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

177 more — sign in →

All 182 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 314 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 823 studies in Hematologic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This was a long-term, continued treatment study that evaluated the long-term safety, clinical activity, and overall survival (OS) of duvelisib in individuals with hematologic malignancies that were previously treated with duvelisib in a previous sponsor-approved study.

Read the detailed description

Study IPI-145-23 was an international, multicenter, open-label, single-arm, Phase 2 study designed to evaluate the long-term safety, clinical activity, and overall survival data of duvelisib in individuals with hematologic malignancies. Only individuals who have participated in a previous duvelisib study that were approved by the sponsor were allowed to enroll in the study.

Participants in active treatment and participants in survival follow-up were allowed to rollover to this study. For participants on active treatment, participants continued the same dose from their previous duvelisib study administered twice daily for 28-day continuous cycles until disease progression or unacceptable toxicity and then followed in a survival follow-up period. For participants in survival follow-up, participants continued to be followed-up for survival in this study for the duration as outlined in their previous duvelisib study.

03

Conditions studied

  • Hematologic Malignancy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have participated in a previous study of duvelisib, and:

    • Be actively receiving duvelisib monotherapy on the previous study (within 14 days of study entry) and demonstrating clinical benefit (complete response [CR]/ partial response [PR]/ stable disease [SD]) of continued use, or
    • Be in the survival follow-up phase of a previous duvelisib study
  • Have completed the required components of the previous study and be appropriate for enrollment into this long-term continued treatment and follow-up study, as determined by the Sponsor

Exclusion criteria

Exclusion Criteria:

  • Had any ongoing ≥ Grade 3 adverse event (AE) considered related to duvelisib treatment at screening
  • Was pregnant or nursing
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Duvelisib

    Participants received the same dose from their previous duvelisib study. All doses were taken twice daily. Two dose reductions were allowed per participant, but doses were not less than 10 milligrams (mg). Participants received duvelisib until disease progression or unacceptable toxicity.

    Drug: Duvelisib

Interventions

  • Administered as oral capsules

    Also known as: IPI-145, VS-0145, COPIKTRA

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Up to 45 months

Secondary outcomes

  1. Best Overall Response (BOR) to Duvelisib as Assessed by the Investigator

    There were no formal secondary endpoints planned and captured data was based on disease response assessment and overall survival (OS) as defined in the participant's previous study. BOR was defined as the best time point response that a participant achieves during the study, with the response ranked according to the following order (from best to worst): complete response (CR), complete response with incomplete marrow recovery (CRi), partial response (PR), stable disease (SD).

    Time frame: Up to 45 months

  2. Overall Survival (OS)

    No formal secondary endpoints were planned for this study. OS was monitored in participants who continued to receive duvelisib treatment and/or in the long-term survival follow-up period in a previous duvelisib study and the number of participants alive at end of study were reported. Participants being followed for OS were contacted by the study site approximately every 6 months to collect survival status and data pertaining to any other alternative antineoplastic therapy.

    Time frame: Up to 45 months

07

Results

Posted Feb 21, 2023

Participant flow

A total of 19 participants were enrolled in the current study from 3 previous studies: IPI-145-01(NCT01549106), IPI-145-02 (NCT01476657), and IPI-145-08 (NCT02204982).

Participant flow — Overall Study
MilestoneDuvelisib
Started19
Received at least 1 dose of study drug19
Completed9
Not completed10
Withdrew: Death5
Withdrew: Lost to follow-up1
Withdrew: Completed follow-up3
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryNumber of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Up to 45 months
Reported as:
Count of participants · Participants
Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
ParticipantsDuvelisib
Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)17
SecondaryBest Overall Response (BOR) to Duvelisib as Assessed by the Investigator

There were no formal secondary endpoints planned and captured data was based on disease response assessment and overall survival (OS) as defined in the participant's previous study. BOR was defined as the best time point response that a participant achieves during the study, with the response ranked according to the following order (from best to worst): complete response (CR), complete response with incomplete marrow recovery (CRi), partial response (PR), stable disease (SD).

Time frame:
Up to 45 months
Reported as:
Count of participants · Participants
Best Overall Response (BOR) to Duvelisib as Assessed by the Investigator
ParticipantsDuvelisib
CR/CRi9
PR5
SD1
Response not evaluable1
SecondaryOverall Survival (OS)

No formal secondary endpoints were planned for this study. OS was monitored in participants who continued to receive duvelisib treatment and/or in the long-term survival follow-up period in a previous duvelisib study and the number of participants alive at end of study were reported. Participants being followed for OS were contacted by the study site approximately every 6 months to collect survival status and data pertaining to any other alternative antineoplastic therapy.

Time frame:
Up to 45 months
Reported as:
Count of participants · Participants
Overall Survival (OS)
ParticipantsDuvelisib
Overall Survival (OS)14

Adverse events

Collected over Up to 45 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Duvelisib5/19 (26.3%)5/19 (26.3%)16/19 (84.2%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventDuvelisib
DiarrhoeaGastrointestinal disorders1/19
EnteritisGastrointestinal disorders1/19
FatigueGeneral disorders1/19
PyrexiaGeneral disorders1/19
Pneumonia cytomegaloviralInfections and infestations1/19
Pneumonia viralInfections and infestations1/19
Pseudomonal sepsisInfections and infestations1/19
FallInjury, poisoning and procedural complications1/19
HypokalaemiaMetabolism and nutrition disorders1/19
HyponatraemiaMetabolism and nutrition disorders1/19
Most frequent other events
Showing 10 of 61
Most frequent other events
EventDuvelisib
DiarrhoeaGastrointestinal disorders5/19
AnaemiaBlood and lymphatic system disorders4/19
FatigueGeneral disorders4/19
Upper respiratory tract infectionInfections and infestations4/19
Abdominal painGastrointestinal disorders3/19
HypokalaemiaMetabolism and nutrition disorders3/19
NeutropeniaBlood and lymphatic system disorders2/19
Oedema peripheralGeneral disorders2/19
PyrexiaGeneral disorders2/19
InfluenzaInfections and infestations2/19

Baseline characteristics

All Treated Analysis Set included all participants who received at least one dose of duvelisib.

Age, Continuous
Age, Continuous(years)Duvelisib
Mean63.8 ± 10.84
Sex: Female, Male
Sex: Female, Male(Participants)Duvelisib
Female11
Male8
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Duvelisib
Hispanic or Latino0
Not Hispanic or Latino19
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Duvelisib
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White18
More than one race0
Unknown or Not Reported0
08

Study locations

5 sites
  • Denver, Colorado 80218, United States
  • Sarasota, Florida 34232, United States
  • Nashville, Tennessee 37203, United States
  • UT MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Azienda Ospedaliera Santa Maria di Terni/SC Oncoematologia
    Terni, Umbria 05100, Italy
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in May 2020, 49 months.

Results were first posted in Feb 2023, 2 years 9 months after primary completion.

Of 136 phase 2 interventional studies under Hematologic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 94. This study's 49 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2016
First posted
Mar 17, 2016
StartActual
Apr 2016
Primary completionActual
May 4, 2020
CompletionActual
May 4, 2020
Results first posted
Feb 21, 2023
Last update
Sep 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02711852
Lead sponsor
SecuraBio
Responsible party
Sponsor
First posted
Mar 17, 2016
Start date
Apr 2016
Primary completion
May 4, 2020
Completion
May 4, 2020
Results posted
Feb 21, 2023
Last update
Sep 11, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Duvelisib

Start the discussion